Jan 13 (Reuters) - Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
Dealmakers are anticipating a surge in megadeals worth over $10 billion, buoyed by hopes of a more lenient antitrust environment under the incoming Trump administration.
The following is a list of deals that took place on Monday ahead of the JPMorgan Healthcare Conference:
GSK-IDRx
British drugmaker GSK GSK.L said that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx.
J&J-Intra-Cellular Therapies
Johnson & Johnson JNJ.N said it will buy Intra-Cellular Therapies ITCI.O for $14.6 billion, with plans to fund the deal through a combination of cash and debt.
Eli Lilly-Scorpion Therapeutics
Eli Lilly LLY.N plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
AbbVie-Simcere Pharmaceutical
AbbVie ABBV.N has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's 2096.HK unit for markets outside China, in a deal valued at up to $1.06 billion.
(Reporting by Kamal Choudhury and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。